Buscar resultados de ensayos clínicos

Patrocinado por

Multiple Endocrine Neoplasia - 16 Studies Found

Estado Estudiar
Active, not recruiting Nombre del estudio: Psychosocial Aspects of Multiple Endocrine Neoplasia (MEN) Syndromes
Condición: Multiple Endocrine Neoplasia
Fecha: 2007-07-12
Intervenciones: Behavioral: Questionnaire Mailed packets including cover letter describing purpose of study, study quest
Completed Nombre del estudio: Registry for Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2
Condición: Multiple Endocrine Neoplasia Syndromes
Fecha: 2017-02-07
Intervenciones: Behavioral: Questionnaires Multiple Endocrine Neoplasia Sy
Completed Nombre del estudio: Vancomycin Associated Red Man Syndrome (RMS)
Condición: Red Man Syndrome
Fecha: 2009-01-14
Completed Nombre del estudio: Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients
Condición: Multiple Endocrine Neoplasia
Fecha: 2017-02-07
Completed Nombre del estudio: Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)
Condición:
  • Multiple Endocrine Neoplasia
  • Pancreatic Neuroendocrine Tumors Fecha: 2017-02-13
    Intervenciones:
    • Other: Genome Sequencing Analy
Completed Nombre del estudio: Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients
Condición:
  • Medullary Thyroid Carcinoma
  • Multiple Endocrine Neoplasia Type 2
    Fecha: 2011-08-26
Active, not recruiting Nombre del estudio: Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
Condición:
  • Medullary Thyroid Carcinoma
  • Multiple Endocrine Neoplasia Type 2
    Fecha: 2007-08-08
    Intervenciones: Drug: Vandetanib once daily continuously (28 day cycles)
Not yet recruiting Nombre del estudio: Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment
Condición: Pancreatic Neuroendocrine Tumors in MEN1
Fecha: 2016-03-02
Intervenciones: Drug: Somatostatin-Analog A long-acting somatostatin-analog will be applied.
Completed Nombre del estudio: High Dose Somatostatin Analogues in Neuroendocrine Tumors
Condición:
  • Respiratory Tract Neoplasms
  • Thymic Neoplasms
  • Pancreatic Ne
    Fecha: 2009-10-05
    Intervenciones: Drug: Octreotide-LAR Octreotide-LAR 30 mg administered every 21 days until progression
Terminated Nombre del estudio: A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Condición:
  • Neuroendocrine Tumors
  • Carcinoid Tumors
  • Adrenal Gland Tumor
    Fecha: 2009-07-23
    Intervenciones:
    • Drug: pertuzumab 840 mg, 420 m
Next >>>